TAF
NBIX icon

Tredje AP-fonden’s Neurocrine Biosciences NBIX Stock Holding History

Tredje AP-fonden’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.23M Buy
54,775
+12,401
+29% +$1.84M 0.04% 337
2026
Q1 		$5.58M Sell
42,374
-42,129
-50% -$5.59M 0.03% 440
2025
Q4 		$12M Buy
84,503
+72,876
+627% +$10.6M 0.09% 146
2025
Q3 		$1.63M Buy
11,627
+951
+9% +$129K 0.01% 303
2025
Q2 		$1.34M Sell
10,676
-26,392
-71% -$3.03M 0.01% 306
2025
Q1 		$4.1M Buy
37,068
+27,704
+296% +$3.51M 0.04% 163
2024
Q4 		$1.28M Sell
9,364
-9,364
-50% -$1.16M 0.01% 356
2024
Q3 		$2.16M Hold
18,728
– – 0.02% 354
2024
Q2 		$2.58M Sell
18,728
-289
-2% -$39.6K 0.02% 306
2024
Q1 		$2.62M Buy
19,017
+3,557
+23% +$486K 0.03% 318
2023
Q4 		$2.04M Sell
15,460
-649
-4% -$74.7K 0.03% 376
2023
Q3 		$1.81M Sell
16,109
-1,494
-8% -$157K 0.03% 380
2023
Q2 		$1.66M Sell
17,603
-2,782
-14% -$272K 0.02% 422
2023
Q1 		$2.06M Buy
20,385
+1,051
+5% +$109K 0.03% 387
2022
Q4 		$2.31M Sell
19,334
-115
-0.6% -$13.5K 0.04% 341
2022
Q3 		$2.07M Buy
+19,449
New +$1.97M 0.04% 333

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tredje AP-fonden's NBIX Position: Q2 2026 in Review

Tredje AP-fonden increased its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, buying an estimated $1.84M and bringing the position to 54,775 shares worth $9.23M. The position accounts for 0.04% of the portfolio, ranked #337.

Tredje AP-fonden first reported a position in NBIX in Q3 2022 and has held it in 16 quarters since. The position peaked at $12M in Q4 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Tredje AP-fonden held 54,775 shares of Neurocrine Biosciences worth $9.23M as of Q2 2026.
  • Tredje AP-fonden bought 12,401 Neurocrine Biosciences shares in Q2 2026, an estimated $1.84M.
  • Neurocrine Biosciences made up 0.04% of Tredje AP-fonden's portfolio in Q2 2026, its #337 holding.
  • Tredje AP-fonden first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 16 quarters since.
  • Tredje AP-fonden's Neurocrine Biosciences position peaked at $12M in Q4 2025.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Tredje AP-fonden's 13F filing for Q2 2026, filed 10 Aug 2026.